Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + 5-fluorouracil based doublet chemotherapy
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the monoclonal antibody bevacizumab (Avastin) administered alongside a 5-fluorouracil (5-FU) based doublet chemotherapy regimen, typically FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan). Developed by Hoffmann-La Roche, this regimen is utilized as a neoadjuvant treatment for patients with previously untreated, unresectable liver-only metastatic colorectal cancer. Bevacizumab functions by binding to vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis and tumor vascularization. The chemotherapy components provide cytotoxic effects: 5-FU acts as an antimetabolite inhibiting thymidylate synthase, while oxaliplatin causes DNA cross-linking and irinotecan inhibits topoisomerase I, collectively leading to tumor cell death and potential downsizing of metastases to allow for surgical resection.
- Other names
- Bevacizumab plus FOLFOXBevacizumab plus FOLFIRIBevacizumab plus 5-FU/LV/oxaliplatinBevacizumab plus 5-FU/LV/irinotecan
02
Targets
Beyond the preview
Go deeper on bevacizumab + 5-fluorouracil based doublet chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + 5-fluorouracil based doublet chemotherapy.